4.7 Article

Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases

期刊

EUROPEAN HEART JOURNAL
卷 37, 期 23, 页码 1850-1858

出版社

OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehv727

关键词

Dilated cardiomyopathy; Position statement; Heart failure

资金

  1. Roche Diagnostics
  2. Novartis
  3. MyoKardia
  4. Shire HGT
  5. Genzyme a sanofi comp.
  6. Amicus Therpautics
  7. Actelion Pharmaceuticals
  8. Boehringer Ingelheim
  9. Genzyme
  10. Shire
  11. Pfizer
  12. Amicus

向作者/读者索取更多资源

In this paper the Working Group on Myocardial and Pericardial Disease proposes a revised definition of dilated cardiomyopathy (DCM) in an attempt to bridge the gap between our recent understanding of the disease spectrum and its clinical presentation in relatives, which is key for early diagnosis and the institution of potential preventative measures. We also provide practical hints to identify subsets of the DCM syndrome where aetiology directed management has great clinical relevance.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据